Document Detail

Extended use of a percutaneous left-ventricular assist device without a heparin-based purge solution.
MedLine Citation:
PMID:  20966145     Owner:  NLM     Status:  In-Process    
PURPOSE: The extended use of an Impella LP 2.5 percutaneous left-ventricular assist device (pVAD) without a heparin-based purge solution in a patient who developed cardiogenic shock after acute myocardial infarction (AMI) is described.
SUMMARY: A 58-year-old Asian man with no history of cardiac disease, hypertension, or diabetes mellitus had an AMI and subsequent cardiogenic shock. He was started on dopamine and norepinephrine and transferred to a tertiary care center for rescue percutaneous coronary intervention (PCI). Given that his artery was patent with Thrombolysis In Myocardial Infarction 3 flow, PCI was not attempted. He had an ejection fraction of 25% and mid-distal anteroseptal akinesis. He was transferred to the intensive care unit on intra-aortic balloon pump (IABP) support. The patient's condition continued to deteriorate, and an Impella LP 2.5 pVAD was inserted for additional hemodynamic support and as a bridge to definitive revascularization. To reduce the potential for medication error and decrease the patient's bleeding risk, the purge solution was changed to 20% dextrose injection without heparin and continued at a rate of 15 mL/hr. The patient's hemodynamic values improved, and the pVAD and IABP were continued for the next five days. The patient was successfully anticoagulated with i.v. heparin throughout the remainder of pVAD support. While the patient did develop hemolytic anemia during his device support, there were no thrombotic or bleeding complications.
CONCLUSION: An Impella LP 2.5 pVAD was used for 75 hours with a purge solution that contained no heparin. There were no thrombotic or bleeding complications.
Douglas L Jennings; Carrie W Nemerovski; Akshay Khandelwal
Related Documents :
11082385 - Deloading of the left ventricle by ventricular assist device normalizes increased expre...
11673145 - Coronary artery exposure in off-pump cabg: a word of caution.
9158275 - Inhaled nitric oxide for right ventricular dysfunction following cardiac transplantation.
4547165 - Complete left ventricular bypass with a paracorporeal pump: design and evaluation.
3050135 - Molecular biology in cardiology, a paradigmatic shift.
24563875 - Can left ventricular parameters examined by gated myocardial perfusion scintigraphy and...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  67     ISSN:  1535-2900     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1825-8     Citation Subset:  IM    
Cardiovascular Intensive Care Unit, Department of Pharmacy Services, Henry Ford Hospital, Detroit, MI, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Standard of care and novel treatments for chronic lymphocytic leukemia.
Next Document:  Rhabdomyolysis in a patient receiving ranolazine and simvastatin.